title: Association of a CYP4A11 variant and blood pressure in black men.
abstract: CYP4A11 arachidonic acid monooxygenase oxidizes endogenous arachidonic acid to 20-hydroxyeicosatetraenoic acid, a renal vasoconstrictor and natriuretic. Cyp4a deficiency causes hypertension in male mice, and a loss-of-function variant (T8590C) of CYP4A11 is associated with hypertension in white individuals. Hypertension and hypertensive renal disease are more common among black than white individuals, but the relationship between genetic variation at CYP4A11 and hypertension in black individuals is not known. This study tested the hypothesis that the CYP4A11 T8590C polymorphism is associated with higher BP or clinical outcomes in 732 black Americans with hypertensive renal disease participating in the African American Study of Kidney Disease (AASK). Men with the 8590CC genotype had significantly higher systolic BP (CC 156.5 +/- 22.6 versus 148.4 +/- 24.3 mmHg in CT and TT combined; P = 0.04) and pulse pressure (P = 0.04) at baseline; this association was not observed among women. In addition, this genotype was associated with higher systolic and diastolic BP at 36-mo follow-up among those randomly assigned to the lower BP arm of the AASK. Among all participants (or men but not women) with proteinuria, the 8590CC genotype was associated with an increased cumulative incidence of ESRD or death, controlling for randomization and clinical characteristics. In summary, the CYP4A11 8590CC genotype is associated with increased BP in black men with hypertensive nephrosclerosis and is associated with adverse clinical outcomes in those with baseline proteinuria. These data support a role for renal monooxygenases and 20-hydroxyeicosatetraenoic acid in the regulation of BP and renal function in men.
authors.affiliation: Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232-6602, USA.
authors.forename: James V
authors.initials: JV
authors.lastname: Gainer
authors.forename: Michael S
authors.initials: MS
authors.lastname: Lipkowitz
authors.forename: Chang
authors.initials: C
authors.lastname: Yu
authors.forename: Michael R
authors.initials: MR
authors.lastname: Waterman
authors.forename: Elliott P
authors.initials: EP
authors.lastname: Dawson
authors.forename: Jorge H
authors.initials: JH
authors.lastname: Capdevila
authors.forename: Nancy J
authors.initials: NJ
authors.lastname: Brown
mesh_terms: D000328:Adult; D001741:Black or African American / Q000235:genetics*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000235:genetics*; D042926:Cytochrome P-450 CYP4A; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D018450:Disease Progression; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009400:Nephrosclerosis / Q000209:etiology*; D012727:Sex Characteristics
chemical_list: D000959:Antihypertensive Agents; D003577:Cytochrome P-450 Enzyme System; C465478:CYP4A11 protein, human; D042926:Cytochrome P-450 CYP4A